Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,143
  • Shares Outstanding, K 55,102
  • Annual Sales, $ 21,200 K
  • Annual Income, $ -11,380 K
  • 36-Month Beta 1.11
  • Price/Sales 6.01
  • Price/Cash Flow N/A
  • Price/Book 5.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +18.86%
on 12/20/18
3.75 -10.93%
on 12/28/18
+0.41 (+13.99%)
since 12/18/18
3-Month
2.79 +19.71%
on 12/11/18
3.83 -12.79%
on 10/19/18
-0.35 (-9.49%)
since 10/18/18
52-Week
2.79 +19.71%
on 12/11/18
5.99 -44.24%
on 01/22/18
-2.10 (-38.60%)
since 01/18/18

Most Recent Stories

More News
ChromaDex Corp. and Nestle Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN(R)

ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestle Health Science (NHSc), a global leader pioneering quality science-based nutritional health solutions....

CDXC : 3.34 (-0.60%)
TRU NIAGEN(R) Expands North American Footprint with Product Launch in Canada

ChromaDex Corp. (NASDAQ:CDXC) announced today it has officially launched TRU NIAGEN(R) in Canada, having received regulatory approval for sale by Health Canada. Directly from the innovators behind NIAGEN(R)...

CDXC : 3.34 (-0.60%)
Factors of Influence in 2018, Key Indicators and Opportunity within Procter & Gamble, Qorvo, McDermott International, Chanticleer, ChromaDex, and Taubman Centers -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Procter & Gamble Company...

CCLRU : 13.5000 (+8.00%)
TCO : 50.65 (+0.76%)
CDXC : 3.34 (-0.60%)
PG : 91.42 (+0.86%)
BURG : 1.88 (+11.90%)
MDR : 8.96 (+2.75%)
QRVO : 63.28 (+1.65%)
TRU NIAGEN(R) to be Featured at the American Academy of Anti-Aging Medicine Annual Meeting

ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature TRU NIAGEN (Booth #6095) at the American Academy of Anti-Aging Medicine World Congress, a gathering of physicians, researchers, and healthcare...

CDXC : 3.34 (-0.60%)
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of OraSure Technologies, Inc....

MCRB : 5.71 (+1.06%)
CDXC : 3.34 (-0.60%)
OSUR : 12.19 (+0.91%)
LDL : 24.90 (+5.78%)
SWIR : 15.18 (+0.07%)
CAPR : 0.67 (+7.26%)
ChromaDex to Present at the 11th Annual LD Micro Main Event

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11...

CDXC : 3.34 (-0.60%)
New TRU NIAGEN(R) Stick Packs Target New Audiences and Consumer Needs

ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method of its revolutionary nicotinamide riboside ingredient to promote cellular energy and repair....

CDXC : 3.34 (-0.60%)
ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -9.78%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.34 (-0.60%)
ChromaDex Corporation Reports Third Quarter 2018 Financial Results

- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million -

CDXC : 3.34 (-0.60%)
ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately.

CDXC : 3.34 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CDXC with:

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

2nd Resistance Point 3.56
1st Resistance Point 3.45
Last Price 3.34
1st Support Level 3.25
2nd Support Level 3.16

See More

52-Week High 5.99
Fibonacci 61.8% 4.77
Fibonacci 50% 4.39
Fibonacci 38.2% 4.01
Last Price 3.34
52-Week Low 2.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar